GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (FRA:DMN) » Definitions » Cash Paid for Insurance Activities

Diamyd Medical AB (FRA:DMN) Cash Paid for Insurance Activities


View and export this data going back to 2018. Start your Free Trial

What is Diamyd Medical AB Cash Paid for Insurance Activities?

Cash Paid for Insurance Activities only applicable to companies reporting Cash Flow from Operations in direct method.


Diamyd Medical AB Business Description

Industry
Traded in Other Exchanges
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.